Administrative Details Regarding the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial

(February 10, 2010)

ClinicalTrials.gov Identifier: NCT00000620

Funding Support
This work was supported by National Heart Lung and Blood Institute contracts N01-HC-95178, N01-HC-95179, N01-HC-95180, N01-HC-95181, N01-HC-95182, N01-HC-95183, N01-HC-95184, and IAA #Y1-HC-9035 and IAA#Y1-HC-1010. Other components of the National Institutes of Health, including the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute on Aging, and the National Eye Institute, contributed funding. The Center for Disease Control funded substudies within ACCORD on cost-effectiveness and health-related quality of life. General Clinical Research Centers provide support at many sites.

Acknowledgements
Members of the ACCORD DSMB included: Antonio M. Gotto, Jr. (chair), Kent Bailey, Dorothy Gohdes, Steven Haffner, Roland Hiss, Kenneth Jamerson, Kerry Lee, David Nathan, James Sowers, LeRoy Walters.
The following companies provided study medications, equipment, or supplies: Abbott Laboratories (Abbott Park, IL); Amylin Pharmaceutical (San Diego, CA); AstraZeneca Pharmaceuticals LP (Wilmington, DE); Bayer HealthCare LLC (Tarrytown, NY); Closer Healthcare Inc. (Tequesta, FL); GlaxoSmithKline Pharmaceuticals (Philadelphia, PA); King Pharmaceuticals, Inc. (Bristol, TN); Merck & Co., Inc. (Whitehouse Station, NJ); Novartis Pharmaceuticals, Inc. (East Hanover, NJ); Novo Nordisk, Inc. (Princeton, NJ); Omron Healthcare, Inc. (Schaumburg, IL); Sanofi-Aventis U.S. (Bridgewater, NJ); Schering-Plough Corporation (Kenilworth, NJ); Takeda Pharmaceuticals (Deerfield, IL).